Traumatic brain injury (TBI) is increasingly appreciated to be highly prevalent and deleterious to neurological function 1, 2 . At present, no effective treatment options are available, and little is known about the complex cellular response to TBI during its acute phase. To gain insights into TBI pathogenesis, we developed a novel murine closedskull brain injury model that mirrors some pathological features associated with mild TBI in humans and used long-term intravital microscopy to study the dynamics of the injury response from its inception. Here we demonstrate that acute brain injury induces vascular damage, meningeal cell death, and the generation of reactive oxygen species (ROS) that ultimately breach the glial limitans and promote spread of the injury into the parenchyma. In response, the brain elicits a neuroprotective, purinergic-receptor-dependent inflammatory response characterized by meningeal neutrophil swarming and microglial reconstitution of the damaged glial limitans. We also show that the skull bone is permeable to small-molecular-weight compounds, and use this delivery route to modulate inflammation and therapeutically ameliorate brain injury through transcranial administration of the ROS scavenger, glutathione. Our results shed light on the acute cellular response to TBI and provide a means to locally deliver therapeutic compounds to the site of injury.
Traumatic brain injury (TBI) is increasingly appreciated to be highly prevalent and deleterious to neurological function 1, 2 . At present, no effective treatment options are available, and little is known about the complex cellular response to TBI during its acute phase. To gain insights into TBI pathogenesis, we developed a novel murine closedskull brain injury model that mirrors some pathological features associated with mild TBI in humans and used long-term intravital microscopy to study the dynamics of the injury response from its inception. Here we demonstrate that acute brain injury induces vascular damage, meningeal cell death, and the generation of reactive oxygen species (ROS) that ultimately breach the glial limitans and promote spread of the injury into the parenchyma. In response, the brain elicits a neuroprotective, purinergic-receptor-dependent inflammatory response characterized by meningeal neutrophil swarming and microglial reconstitution of the damaged glial limitans. We also show that the skull bone is permeable to small-molecular-weight compounds, and use this delivery route to modulate inflammation and therapeutically ameliorate brain injury through transcranial administration of the ROS scavenger, glutathione. Our results shed light on the acute cellular response to TBI and provide a means to locally deliver therapeutic compounds to the site of injury.
TBI encompasses injuries that range from mild to severe 1, 3 , and occurs when the brain is exposed to external forces that induce focal and/or diffuse pathologies, including vascular damage, oedema, axonal shearing and neuronal cell death [4] [5] [6] . TBI is usually divided into two phases: the primary insult and the ensuing secondary reaction. It is postulated that primary cell death cannot be prevented without avoiding the injury itself, but that secondary damage is amenable to therapeutic intervention because it is driven by pathogenic parameters such as ROS 7, 8 , calcium release 9 , glutamate toxicity 10, 11 , mitochondrial dysfunction 12 , inflammation 6 , and so on. Animal models of TBI have been developed that reflect mild, moderate and severe forms of injury 5 , but therapeutic research in these models has not yet translated successfully into the clinic 4, 13 . Thus, there is an increasing need to develop additional TBI models, temporally map the dynamics of brain injury responses, and devise therapeutic interventions.
In humans, primary injury to the meninges and vasculature can be observed in the absence of conspicuous brain damage after minor head trauma. As part of an ongoing study of mild TBI, we evaluated research magnetic resonance imaging (MRI) with contrast from patients presenting to the emergency room within 48 h of a minor head injury. Over a period of 30 months, 142 patients were enrolled with a baseline Glasgow Coma Scale of 15, reporting loss of consciousness or posttraumatic amnesia, and a clinical computed tomography (CT) scan without evidence of injury to the parenchyma. Meningeal haemorrhage was seen on CT in 18 patients (12.7%), including subarachnoid blood in 13 (9.1%) and subdural blood in 7 (4.9%). Focal enhancement of the meninges was observed on post-contrast fluid attenuated inversion recovery (FLAIR) MRI imaging ( Fig. 1a ) in 69 (48.6%) patients, and without concomitant meningeal haemorrhage in 53 (36.9%) patients. Enhancement is the result of extravasation of gadolinium contrast into space containing free fluid with a T1 relaxation time constant equivalent to that of cerebrospinal fluid (CSF) 14 .
To understand better the immunopathogenesis of focal brain injury, we developed a novel closed-skull model of mild TBI amenable to intravital imaging studies. Thinning the murine skull bone to ,30 mm allows the underlying meninges and brain parenchyma to be imaged by twophoton laser scanning microscopy (TPM) without overt brain injury or inflammation 15 . Thinning the skull bone beyond 30 mm causes increased pliability and concavity, which compresses the meningeal space (referred to as a compression injury) (Extended Data Fig. 1 ). Sequential thinning of the skull bone from 50 to 10 mm induced increasing amounts of meningeal cell death ( Fig. 1b ). Cell death and inflammation associated with over-thinning was reproducibly generated by quickly thinning the skull bone to ,20-30 mm and then manually promoting concavity with minimal downward pressure (Extended Data Fig. 1 ). We used this model to define the dynamics of inflammation and the mechanisms that cause cell death after focal TBI.
Using TPM we first mapped the kinetics and severity of brain pathology, starting 5 min after compression injury. Immediately after injury quantum dots injected intravenously leaked from vessels into the subarachnoid and perivascular spaces ( Fig. 1c and Supplementary Video 1). Within 30 min, ROS were detected in the meninges ( Fig. 1d ) and holes appeared in the glial limitans due to astrocyte cell death ( Fig. 1e and Supplementary Video 1). Transcranially administered SR101, a 600 molecular weight (MW) dye, leaked through the glial limitans into the parenchyma after compression injury, but remained largely within the meningeal space after standard skull thinning ( Fig. 1f ). Compression also induced cell death in the meninges that increased steadily over time, but was not observed in the parenchyma until 9-12 h after injury ( Fig. 1g, h ). Parenchymal cell death at 12 h was indiscriminate, as neurons, astrocytes, oligodendrocytes and microglia were all lost in the lesion site (Extended Data Fig. 2 ).
We next sought insights into the dynamics of the innate inflammatory response. Meningeal macrophages (long, rod-like cells) died within 30 min of compression injury ( Fig. 2a and Supplementary Video 1). In response to meningeal cell death, microglia extended processes through the compromised glial limitans into the meninges (Extended Data Fig. 3a and Supplementary Video 1). We also observed a coordinated microglial response to compression injury. Most microglia within 50 mm of the meninges retracted all processes except for ,2-3 that extended towards the glial limitans, forming a stable contiguous network resembling a 'honeycomb' structure ( Fig. 2b and Supplementary Video 2). Long-term TPM revealed that the honeycomb network formed within an hour of injury and could be maintained for up to 12 h (Supplementary Video 2). Honeycomb microglia surrounded surviving astrocytes in the glial limitans and aligned with the junctions between individual cells (Extended Data Fig. 3b and Supplementary Video 2).
In response to astrocyte death ( Fig. 1d and Supplementary Video 1), a morphologically distinct microglial reaction was observed; microglia retracted their ramified processes and extended a single, non-branching process towards the glial limitans that resembled a jellyfish ( Fig. 2c , Extended Data Fig. 3b and Supplementary Video 3). 'Jellyfish' microglia started to form almost immediately after compression injury (Supplementary Videos 3, 4), and some were motile, whereas others remained stationary (Supplementary Videos 3-5). We commonly observed honeycomb networks of microglia interspersed with clusters of jellyfish microglia (Supplementary Videos 4, 5), which probably reflects variation in lesion severity along the glial limitans. Honeycomb microglia could even transform within 5 min into jellyfish microglia, presumably after astrocyte cell death (Supplementary Video 5), whereas naive microglia required ,30 min to acquire a jellyfish morphology. Jellyfish projections were usually linked to cell bodies via thin processes (Supplementary Video 6) and often formed a continuous phagocytic layer at the glial limitans ( Fig. 2c , Extended Data Fig. 3b and Supplementary Videos 3, 6, 7). Over time, microglia residing in the glial limitans died, particularly after tissue swelling (or oedema) was observed (Supplementary Video 7). Peripherally derived myelomonocytic cells (neutrophils and monocytes) also responded to brain damage. Within an hour of compression injury, b-d, f, g, Maximum projections (5 mm wide) are shown in the xz plane of two-photon z-stacks captured through a thinned murine skull. b, Images of skull bone (blue) and underlying meninges show sequential skull thinning from 50 to 10 mm. Dead cells (red) were labelled by transcranial propidium iodide (PI) administration. Scale bar, 50 mm. c, Intravenously injected Q-dots (red) leak from blood vessels into the meninges 15 min after compression injury, indicative of vascular damage. Scale bar, 50 mm. d, ROS (red) labelled with Amplex Red appear in the meninges 30 min after compression injury of CX3CR1 gfp/1 (green) mice relative to uncompressed controls. White dotted line indicates the glial limitans. macs, macrophages. Scale bar, 30 mm. e, xy maximal projections (25 mm in depth) captured in GFAP-GFP mice show holes (white arrows) in the glial limitans as a result of astrocyte (green) death, which starts to occur 5 min after compression injury. Scale bar, 50 mm. f, Transcranially applied SR101 (red) diffuses into the brain parenchyma 30 min after injury, but is largely excluded from the parenchyma in an uncompressed control mouse. Scale bar, 50 mm. g, Cell death (PI 1 cells; red) becomes apparent in the brain parenchyma 12 h after compression injury and is not observed in uncompressed controls. Scale bar, 50 mm. h, Quantification of cell death (mean 1 standard deviation (s.d.)) in the meninges and parenchyma after compression injury. All data in the figure are representative of three mice per group (four mice, g) and at least three independent experiments.
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myelomonocytic cells (probably neutrophils) localized exclusively to the meninges, were highly motile, and interacted with dead cells during the 12 h observation period ( Fig. 2d and Supplementary Video 8).
To modulate TBI lesions locally, we applied compounds to the intact skull bone. We discovered that SR101, when applied to an intact (nonthinned) skull bone passed directly into the meninges within 10 min (referred to as a 'transcranial application') ( Fig. 3a) . We next tested a range of differently sized fluorescent dextrans (3,000-70,000 MW).
Dextrans of 40,000 MW and below were able to pass through the intact skull into the meninges (Fig. 3b ), although larger dextrans required longer diffusion times ( Fig. 3c ). A 70,000 MW dextran was unable to pass transcranially in 30 min. In addition, a variety of fluorescent small molecules and macromolecules passed through the murine skull bone and achieved measurable steady-state concentrations in the meninges dependent on molecular weight ( Fig. 3d and Extended Data Fig. 4 ). Passage through an intact skull yielded a meningeal concentration approximately one half that achieved by thinned skull application (Extended Data Fig. 4d, e ). We assessed the feasibility of passing compounds through thicker skulls by applying the contrast agent manganese chloride to an MW fluorescent dye, SR101 (red), was applied to an intact mouse skull for the indicated time and then the skull (blue) was quickly thinned and imaged. Five micrometre xz maximum projections show that SR101 is detectable in the meninges beginning 10 min after application and fully saturates the space within 15 min. White dotted line indicates glial limitans. Scale bar, 50 mm. b, The size dependence of diffusion through an intact skull bone was evaluated 30 min after continuous transcranial application of the indicated molecular weight dextrans (red). Dextrans that passed successfully through the skull generated fluorescence in the meninges. The skull bone is shown in blue, and the glial limitans is denoted with a white dotted line. Scale bar, 50 mm. c, A colour-coded table summarizing the imaging results shown in panels a and b denotes the presence (green) or absence (red) of fluorescent dye in the meninges at the indicated molecular weight and time. Grey, not tested. d, Fluorescent compounds of increasing molecular weights were passed transcranially through a thinned skull window during imaging. Steady-state concentrations (mean 1 s.d.) of the fluorescent compounds in the meninges and parenchyma were quantified from normalized fluorescence intensities. See also Extended Data Fig. 4 . e, Manganese chloride (Mn; 500 mM solution) applied transcranially to an intact rat skull (,1 mm thick) is visible by MRI in the brain parenchyma 2 h after application (white arrow). The mean parenchymal manganese concentration 6 s.d. is provided. Scale bar, 1 mm. All data in the figure are representative of three mice (or rats) per group and at least three independent experiments.
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intact rat skull bone (,1 mm thick) and imaging transcranial passage by MRI ( Fig. 3e ). Transcranially applied manganese chloride was clearly visible in the rat brain parenchyma 2 h after application. We next defined the mechanisms underlying compression injuryinduced inflammation. Trancranial application of purinergic receptor 16 (P2RY12 or P2RX4) inhibitors before compression injury prevented both honeycomb and jellyfish morphologies, whereas P2RY6 antagonism only blocked the jellyfish response ( Fig. 4a, b , Extended Data Fig. 5a and Supplementary Video 9). In contrast, P2RX7 antagonism had no effect on microglia, but almost entirely eliminated neutrophil recruitment ( Fig. 4a -c, Extended Data Fig. 5b and Supplementary Video 9). Astrocytes are known to amplify purinergic receptor signalling through ATP-induced ATP release via connexin hemichannels, which can be blocked with carbenoxolone (CBX) 17 . Transcranial application of CBX, but not a specific pannexin inhibitor (probenecid), before compression injury caused microglia to remain ramified, extending only small, ill-defined circular processes at the glial limitans, similar to what was observed after P2RY6 antagonism ( Fig. 4d , e, Extended Data Fig. 5c and Supplementary Video 9). CBX inhibited the formation of honeycomb and jellyfish microglia, whereas pannexin inhibition slowed the onset and magnitude of neutrophil recruitment ( Fig. 4f ). Pre-treatment with CBX also significantly increased SR101 leakage through the glial limitans, suggesting that ATP release by astrocytes and purinergic signalling in microglia help maintain barrier integrity between the meninges and parenchyma ( Fig. 4g and Extended Data Fig. 5d ).
To identify the primary mediator of cell death after compression injury, we focused on the role of ROS, which appeared in the meninges shortly after compression injury ( Fig. 1d ). Transcranial administration of the ROS scavenger glutathione (GSH) resulted in near complete survival of meningeal macrophages after a more severe injury (that is, skull fracture) ( Fig. 5a and Supplementary Video 10) as well as glial limitans preservation ( Fig. 5b, f ). In addition, microglia beneath this layer remained in a non-reactive, ramified state ( Fig. 5a , e and Supplementary Video 10). Preservation of the glial limitans after GSH treatment resulted in refilling of the subarachnoid space beneath the compression injury, which pushed the thinned skull bone upward (Supplementary Video 10). GSH administration also eliminated the recruitment of myelomonocytic cells (Fig. 5c, g and Supplementary Video 10).
Cell death was first observed in the meninges and later spread to the parenchyma after compression injury (Fig. 1h ). Transcranial pretreatment with GSH resulted in a 50% reduction in meningeal death, but administration after injury had no effect (Fig. 5h ), indicating that half the initial meningeal cell death following compression injury is due to ROS. GSH, when applied continuously starting at 15 min or 3 h after injury, reduced parenchymal cell death at 12 h by 67% and 51%, respectively ( Fig. 5d, i) . These data indicate that ROS are a mediator of cell death after compression injury. The contribution of inflammation to cell death was assessed by transcranially inhibiting neutrophils and microglia with P2RX7 or P2RY6 antagonism, respectively. Inhibition of neutrophil recruitment through P2RX7 antagonism increased cell death in the meninges 12 h later, but had no impact on parenchymal cell death ( Fig. 5h , i). Conversely, inhibition of microglia through P2RY6 antagonism increased parenchymal cell death at 12 h, but did not affect meningeal cell death ( Fig. 5h , i). These data suggest that inflammation is neuroprotective within the first 12 h of compression injury.
TBI induces a complex reaction that can result in permanent damage and neurological dysfunction. In this study, we observed evidence of meningeal damage in ,50% of patients with mild head injury, indicating that this is a common pathology in humans. We sought mechanistic insights into this process by developing a novel closed-skull model of brain injury and imaging the acute cellular injury response from its inception. Importantly, we discovered that the skull bone is porous and permits the passage of small molecules (#40,000 MW) and contrast agents by passive diffusion, which should facilitate local delivery 
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of therapeutics and other molecules into the central nervous system. Pathologically, compression injury initially caused meningeal cell death, vascular damage, ROS generation, and disruption of the glial limitans, which ultimately gave rise to indiscriminate parenchymal cell death. ROS are commonly observed in TBI lesions 7, 8 , and transcranial delivery of GSH preserved the glial limitans, reduced cell death, and eliminated the sterile injury response. GSH significantly reduced parenchymal cell death even when administered 3 h after injury, providing a therapeutic window for treatment of focal brain injury.
In the absence of GSH, the brain responded to damage by eliciting an anatomically partitioned sterile immune reaction 18 . Microglia first fortified the glial limitans through the generation of honeycomb and jellyfish structures. Honeycomb microglial networks circumscribed individual surviving astrocytes in the glial limitans and were induced to do so by the release of ATP from connexin hemichannels and its detection by purinergic receptors (P2RX4 and P2RY12) 16, 17, 19, 20 . Phagocytic jellyfish microglia were similarly generated by purinergic signalling (P2RX4, P2RY6, P2RY12) and filled areas along the glial limitans in which astrocyte cell death had occurred. Transcranial inhibition of the microglial response through P2RY6 or connexin hemichannel antagonism increased the permeability of the glial limitans and parenchymal cell death after compression injury. Although microglia protected the parenchyma, myelomonocytic cells invaded the damaged meninges in a P2RX7-and pannexin-dependent manner, consistent with a recent study showing P2RX7-dependent neutrophil recruitment into the injured liver 21 . Collectively, our data suggest that the acute inflammatory reaction to brain injury is beneficial 6 . Moreover, ROS and purines represent major drivers of the injury response and are amenable to transcranial therapeutic manipulation.
METHODS SUMMARY
Human patients presenting to the emergency room within 48 h of mild head injury were evaluated as part of an ongoing Traumatic Head Injury Neuroimaging Classification (THINC) study. MRI scans were obtained and evaluated after injection of a gadolinium-based contrast agent. To model the pathology of mild head injury, we surgically thinned the murine skull bone over the barrel cortex to a thickness of ,20-30 mm and then applied minimal downward pressure to promote concavity in the bone (meningeal compression) (Extended Data Fig. 1 ). As a control, a similar surgical procedure was conducted without applying downward pressure. All intravital imaging was performed using a Leica SP5 two-photon microscope and subsequent image analysis was performed using Imaris 7.0 software. Transcranial administration of compounds was achieved by placing compounds resuspended in artificial cerebral spinal fluid (aCSF) directly on top of the exposed skull bone (either thinned or completely intact). Compounds entered the CNS via passive diffusion through the bone. For these experiments, rodents were subsequently imaged using a Leica two-photon microscope or an 11.7-Tesla MRI scanner. Immunohistochemical stains of TBI lesions in mice were imaged using an Olympus FV1200 confocal microscope. 21 ) in PBS and maintained at a core temperature of 37 uC. The skull bone over the barrel cortex was then thinned to a thickness of ,30-40 mm as described 25 . For this procedure, the bone was manually thinned over a 30 min period, and the amount of downward pressure was kept to a minimum. To induce a compression injury, the skull was thinned within 1-2 min to a thickness of ,20-30 mm. Once thinned, the blunt end of a surgical instrument was used to gently press the pliable skull bone downward to promote concavity in the bone. The downward pressure applied was minimal and only performed until a concave bone was observed. This resulted in the skull bone collapsing (without breaking) inward towards the surface of the brain. In one set of experiments, the skull bone was intentionally cracked to induce a severe injury. Imaging was performed beginning 5 min after injury. Intravital two-photon laser scanning microscopy. Mice with a normally thinned or compressed skull bone were imaged using a Leica SP5 two-photon imaging system (Leica Microsystems) equipped with an 8,000 Hz resonant scanner, a 320/ 1.0 NA dipping objective, and two Mai Tai HP DeepSee Lasers (SpectraPhysics) tuned to 905, 920 or 970 nm. Fluorescence emission was separated by high efficiency custom dichroic mirrors (Semrock) and collected with a NDD4 external detector (Leica). Stacks of images were acquired using a step size of 1.0 mm (single stacks) or 2.5 mm (time-lapse videos) to a depth of 150 mm. Time-lapse videos were acquired with 1 min intervals between three-dimensional stacks. For all imaging studies, the 320 lens was submerged directly into artificial cerebral spinal fluid (aCSF; 119 mM NaCl, 26.2 mM NaHCO 3 , 2.5 mm KCl, 1 mM NaH 2 PO 4 , 1.3 mM MgCl 2 , 1.2 mM CaCl 2 , 0.4% glucose, pH 7.4) placed on top of the thinned skull. Fluorescent dyes. To visualize brain vasculature, mice were injected i.v. 10 min before imaging with 50 ml Qtracker 655 nm non-targeted quantum dots in PBS (0.2 mM; Invitrogen). Cell death was visualized by incubating the thinned skull with propidium iodide (1.5 mM) in aCSF for 30 min. This was followed by a single wash with aCSF and then imaging. ROS were visualized by applying Amplex Red (500 mM) transcranially for 10 min. This was followed by immediate imaging. Astrocytes were visualized by transcranially applying SR101 (10 mM) for 30 min. This was followed by a 1 h aCSF wash and then imaging. Immunohistochemistry. To examine the identity of dead cells in the brain parenchyma, a compression injury and normal thin skull procedure were performed on opposite hemispheres of the same skull. Dead cells were labelled by transcranial propidium iodide application, and the mice were perfused with 4% paraformaldehyde (PFA) at 12 h after injury. Whole mouse heads were post-fixed in 4% PFA for 8 h and then stored in 30% sucrose for another 24 h. After decalcification of the skull bone, 6 mm serial coronal brain sections through the injury and control sites were produced by Histoserv. Before antibody staining, sections were blocked with 10% fetal bovine serum (FBS) (GFAP and Iba1 stains), 10% FBS plus 35 mg ml 21 donkey anti-mouse F(ab) (NeuN stain), or 10% FBS plus 35 mg ml 21 donkey antimouse F(ab) plus 0.1% Triton X-100 (APC stain). The following cell types were labelled: neurons (anti-NeuN; 1:800; Chemicon), astrocytes (anti-GFAP; 1:800; DakoCytomation), microglia (anti-Iba1; 1:400; Wako) and oligodendrocytes (anti-APC; 1:50; Oncogene Research). Cell-marker-specific antibodies were detected with secondary antibodies conjugated to Alexa Fluor 488 (1:200; Jackson Immuno-Research Laboratories). Working stocks of primary and secondary reagents were diluted in PBS containing 2% FBS (NeuN, GFAP, IbaI) or 10% FBS with 0.1% Triton X-100 (APC). All sections were incubated with 1 mg ml 21 4,6-diamidino-2phenylindole (DAPI; Sigma-Alderich) for 3 min at room temperature (24 uC) to stain cell nuclei. Confocal microscopy. Two-dimensional images shown in Extended Data Fig. 2 were captured from stained 6-mm frozen sections using an Olympus FV1200 confocal microscope equipped with a 320 objective. Images were collected using sequential scanning with the 405, 488 and 559 nm laser lines to produce three colour overlays.
Purinergic receptor, hemichannel and ROS antagonism. Before skull thinning, antagonists diluted in aCSF were applied directly to the skull bone, and vehicle was simultaneously applied to the opposite hemisphere to serve as a control. The following antagonists from Sigma were used: TNP-ATP hydrase (P2RX4; 25 mM), oxidated ATP (P2RX7; 10 mM), MRS2578 (P2RY6; diluted in a 50 mM DMSO stock 1:100 in aCSF to a final concentration of 500 mM), MeSAMP (P2RY12; 10 mM), CBX (connexin hemichannels; 100 mM), provenecid (pannexin hemichannels; 100 mM) and glutathione (ROS; 100 mM). Vehicle and purinergic receptor antagonists were applied as a 3 mm diameter bubble on the skull surface and replenished as needed over a 30 min incubation period to prevent drying. This allowed the antagonists to continuously pass through the skull bone. After the 30 min incubation, the skull was dried and then thinned to induce a compression injury over both hemispheres. Imaging was initiated immediately after injury. For most studies, the skull bone pre-incubated with antagonists was imaged continuously for 3-10 h, after which a three-dimensional stack was captured from both the vehicle-and antagonist-treated areas for quantitative purposes. Long-term continuous intravital TPM alone did not induce an injury response (data not shown).
Glutathione was also applied at 15 min and 3 h after compression injury to determine the impact on cell death. For these studies, glutathione was added directly to the aCSF submerging solution (100 mM) while imaging. The glutathione was maintained in the submerging solution for the entire imaging experiment. Similar studies were conducted using 10 mM oxidated ATP and 500 mM MRS2578. Glial limitans leakage assay. For permeability studies, areas of skull bone were pre-incubated with vehicle, CBX (100 mM) or glutathione (100 mM) for 30 min as described earlier. Afterwards, a meningeal compression injury was induced. While imaging, antagonists (10 mM CBX or 100 mM glutathione) were added directly to the aCSF submerging solution. After 3 h of imaging, SR101 (1 mM) was applied for 15 min, followed by a 5 min aCSF wash. A three-dimensional stack was then captured to quantify the degree of SR101 leakage through the glial limitans. Skull bone permeability analyses. For skull bone permeability studies, the following rhodamine-labelled dextrans were placed directly on the intact skull bone for up to 30 min: 3,000 MW (25 mM), 10,000 MW (5 mM), 40,000 MW (1 mM) and 70,000 MW (0.5 mM). SR101 (1 mM) was used as a representative 600 MW compound. Compounds were replenished as needed to prevent drying. After the incubation period, the skull bone was quickly thinned and imaged. A three-dimensional stack was captured to determine whether the fluorescence could be found beneath the skull bone. For quantitative analyses of skull bone permeability through a thinned skull window, the following fluorescent compounds were used: Nile Red (318 MW; 100 nM), fluorescein (376 MW; 100 nM), SR101 (606 MW; 100 nM), rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (DHPE) (phospholipid; 1,334 MW; 1 mM), 5-tetramethylrhodamine (TMR)-RRADDSDDDDD (TMR-tagged peptide; 1,706 MW; 100 nM), 59-Rhodamine Red-X-N-ATGAT-39 (Rhodamine-Red-tagged oligonucleotide; 2,335 MW; 1 mM), 3,000 MW dextran (100 nM), 10,000 MW dextran (10 mM) and 40,000 MW dextran (25 mM). Briefly, a thin skull preparation as described earlier was performed on a B6 mouse followed by 30 min of imaging in aCSF to establish a baseline. Without interrupting the imaging sequence, the aCSF was replaced after 30 min with a solution containing the fluorescent compounds at the denoted concentrations and then imaged continually for another 60 min. After acquisition, 100 3 100 3 5 mm (xyz) boxes were created using the 'surfaces' tool in Imaris and placed 25 mm above the skull, in the meninges (0-5 mm below the skull), and in the parenchyma (15-20 mm below the skull). The background fluorescence intensity for each anatomical region was calculated using the first 30 min of imaging. Instantaneous concentrations of fluorescent compounds were then determined from 30 to 90 min (at 1 min intervals) for the skull, meninges and parenchyma by calculating the average fluorescent intensities in the 100 3 100 3 5 mm boxes. After subtracting the background fluorescence, the resultant number was divided by the fluorescent intensity of the applied compound in solution and multiplied by 100 to generate a percentage. To determine the concentrations in the meninges achieved by transcranial loading through an intact murine skull bone, 100 nM SR101 was applied transcranially through the intact skull for 20 min followed by a quick (,2 min) thin skull preparation and
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imaging. The background fluorescence in the meninges and fluorescence intensity of 100 nM SR101 in aCSF were determined in a separate mouse as described earlier.
Transcranial manganese delivery. Rats were anaesthetized with 5% isoflurane and then switched to 1-2% isoflurane for maintenance. Their body temperature was maintained by a heated water bath. The animals were placed in a stereotaxic apparatus, a single midline incision with a sterile scalpel was made through the skin of the skull, and the skull bone was exposed by scraping away the periosteum.
The following sterile saline solutions were placed directly on the skull bone above the S 1 area (left/right, 13; rostral/caudal, 21.4; from Bregma): 500 mM MnCl 2 , 250 mM MnCl 2 (not shown) and pure saline as a control. The solutions were pipetted over a 2 h period and replenished as needed. After 2 h, the skull was rinsed three times with saline, the skin sutured, and the animal promptly placed in an MRI scanner to detect manganese diffusion into the brain. Images were acquired on an 11.7 T/31 cm horizontal magnet (Agilent) interfaced to a Bruker Avance III console (Bruker BioSpin) equipped with a 12 cm gradient set (Resonance Research). A 9 cm laboratory-built birdcage coil was used for signal transmission and a 2 cm surface coil placed on the rat head was used for signal acquisition. During imaging, anaesthesia was maintained at 1.5% isoflurane, and the body temperature was maintained at 37 uC using a heated water bath. Contrast enhancement by manganese was detected using a T 1 -weighted spin echo pulse sequence (TE 5 7.6 ms, TR 5 500 ms, Nav 5 8, 100 mm in-plane resolution, 30 1-mm-thick axial slices). The T 1 relaxation times were measured using a saturation recovery spin-echo sequence (TE 5 7.6 ms, TRs 5 0.4, 0.97, 1.77, 3.124 and 10 s; 200 mm in-plane resolution). Two-photon image analysis. All quantitative analyses and processing of threedimensional/four-dimensional imaging data were performed using Imaris 7.0 software (Bitplane). Supplementary Videos were constructed and annotated using Adobe Premiere Pro CS4. Microglia honeycomb reactions were quantified from 434 3 434 3 150 mm (xyz) three-dimensional image stacks obtained at selected time points in CX3CR1 gfp/1 mice. This was accomplished by measuring the total length of microglial processes in contact with the glial limitans. Microglial cell bodies were first selected using the Imaris 'spots' tool. Afterwards, ten microglia per mouse were randomly selected for quantification of process length. Only cells with all of their processes in the field of view and no more than 50 mm beneath the skull bone were quantified. Microglial processes that were touching (flat against) the glia limitans were labelled and measured using the Imaris 'filaments' tool. Data were then represented on a per cell basis as the length of microglial processes in contact with the glial limitans. Microglia with a jellyfish morphology were identified as those having processes greater than 20 mm in diameter. The number of jellyfish microglia was then divided by the total number of microglia within 50 mm of the skull bone and multiplied by 100 to generate a percentage. To quantify cell death, propidium-iodide-positive cells were labelled in three-dimensional stacks using the Imaris 'spots' tool. Dead cells from 0 to 5 mm below the compressed skull were considered meningeal, whereas cells from 5 to 100 mm were considered parenchymal. The number of dead cells was divided by the volume analysed and represented as cells per mm 3 . Neutrophils were quantified in LysM gfp/1 mice using the Imaris 'spots' tool. After compression injury, neutrophils were never observed in the brain parenchyma and, therefore, were quantified only in the meningeal space (0 to 5 mm below the compressed skull). The number of neutrophils was divided by the volume analysed and represented as cells per mm 3 . To quantify leakage of SR101 through the glial limitans, a 50 3 50 3 100 mm (xyz) solid box was generated using the Imaris 'surfaces' tool. The box was placed 25 mm beneath the epicentre of the compression injury (that is, the lowest point of the compressed skull bone). The mean fluorescent intensity of the SR101 signal inside of this box was then calculated. The value obtained beneath the antagonist-treated skull (glutathione or CBX) was divided by the vehicle control area (from the opposite hemisphere) to generate a fluorescence ratio. MRI image analysis. MRI images from rats receiving transcranial manganese were analysed using ImageJ (http://rsb.info.nih.gov/ij/) and MIPAV (http://mipav.cit.nih. gov/) software developed at NIH. T 1 relaxation maps for brain slices were calculated using the MRI Analysis Calculator plugin. Background tissue T 1 values and standard deviations for every slice were obtained by placing a region of interest (ROI) over an area of the cortex opposite from the one of manganese administration. T 1 relaxation maps were thresholded using the value of the background T 1 minus two standard deviations in order to obtain ROIs in which manganese had significantly shortened the T 1 of the cortex tissue. The average T 1 relaxation times as well as the total number of voxels in those ROIs were used to determine the local concentration and total amount of manganese in each slice, using the equation: 1/(T 1 ) observed 5 1/(T 1 ) background 1 r 1 3 c. The value of 4.7 s 21 mM 21 was used for cortex T 1 relaxivity as previously reported 26 . The total amount of manganese was integrated through the relevant slices. Group sizes and statistical analysis. Group sizes of 3-4 rodents were used for all experiments to ensure reproducibility and that statistical differences could be detected. All experiments were independently replicated at least three times. Only animals that succumbed to anaesthesia were excluded from further analysis. For experiments with experimental and control groups, littermates were randomized before assignment to a particular condition. Statistical significance (P , 0.05) was determined using a Student's t-test (two groups) or a one-way analysis of variance (ANOVA) (more than two groups). A rank sum test or ANOVA on ranks was used for data sets with non-parametric data. All graphs and statistical analyses were performed using SigmaPlot version 11. 
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Extended Data Figure 4 | Pharmacology of transcranial fluorescent compound administration. a-c, Steady-state concentrations (Conc) of fluorescent compounds in aCSF were calculated by two-photon microscopy above the skull (blue) as well as in the meninges (orange) and brain parenchyma (green) for 1 h after transcranial administration through a surgically thinned (uncompressed) skull. Background fluorescence was established by imaging for 30 min before adding the fluorescent compounds. Low molecular weight compounds established higher steady-state concentrations in the meninges than larger compounds. The hydrophobic, low molecular weight compound Nile Red was also able to pass through the glial limitans into the brain parenchyma. See Methods for additional details about the applied fluorescent compounds. Oligonuc., oligonucleotide. d, A 100 nM SR101 solution was applied to an intact mouse skull for 30 min, then immediately thinned and imaged while the skull was submerged in aCSF to determine the decay in the meningeal SR101 concentration over time. e, The bar graph shows a comparison of the meningeal SR101 concentration (mean 6 s.d.) after transcranial application to a thinned versus an intact skull. Data are representative of three mice per group and at least three independent experiments.

